Soluble CD163 impact as a prognostic biomarker in chronic lymphocytic leukemia |
The Egyptian Journal of Immunology Volume 30 (3), July, 2023 Pages: 74 – 81. www.Ejimmunology.org https://doi.org/10.55133/eji.300308 |
|
| Halla M. Ragab1, Hanaa R. M. Attia2, Nabila A. Maksoud1, Mona H. Ibrahim2, Mai M. Abdel Wahed Mohamed2, Abdelkarim Kamel3, Mohamed E. Sobeih4, Mohamed A. M. Kamal5, and Wafaa Abd Elaziz1
|
| 1Department of Biochemistry, National Research Centre, Institute of Biotechnology Research, Cairo, Egypt.
2Department of Clinical & Chemical Pathology, National Research Centre, Institute of Medical Research and Clinical Studies, Centre of Excellence, Cairo, Egypt. 3Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt. 4Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. 5Department of Clinical Pathology, El Hussein Hospital, Al Azhar University, Cairo, Egypt. |
Corresponding author: Halla M. Ragab, Department of Biochemistry, National Research Centre, Institute of Biotechnology Research, Cairo, Egypt. Email: hmragab@yahoo.com. |
Abstract:
Chronic lymphocytic leukemia (CLL) is a malignant blood disorder in which there is an excess of white blood cells (lymphocytes) in blood and lymphoid tissues. CLL patients experience different clinical behaviors with diversity in disease course and outcome. Accordingly, prognostic markers are crucial for employing appropriate therapy protocols. CD163 (cluster of differentiation 163) is a monocyte/macrophage receptor. Soluble CD163 (sCD163) is an emerging prognostic player in the field of hematopoietic neoplasms. This study aimed to assess the prognostic potential of sCD163 as a serological marker in CLL. The study included 41 CLL patients and 44 apparently normal healthy volunteers as controls. Expression of CD38 and cytoplasmic ZAP‑70 in CLL cells was assessed using flow cytometry. Beta 2 microglobulin (B2M), sCD23, and sCD163 serological markers were measured by ELISA. Serum levels of sCD163 were statistically significantly higher in CLL cases compared to controls (p=0.000). sCD163 levels were positively correlated with absolute lymphocyte count, sCD23, and B2M levels (p= 0.027, p=0.01, and p=0.004, respectively). In conclusion, levels of sCD163 in CLL is a promising prognostic tool for evaluating disease progression.
Keywords:
CD163, CLL, ELISA
Date received:
04 February 2023; accepted: 15 May 2023
PMID:
37440184
Full Text